Van Lanschot Kempen Investment Management N.V. Boosts Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Van Lanschot Kempen Investment Management N.V. boosted its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 823,828 shares of the company's stock after purchasing an additional 67,248 shares during the period. Van Lanschot Kempen Investment Management N.V. owned about 0.66% of Henry Schein worth $57,009,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HSIC. Olstein Capital Management L.P. boosted its holdings in shares of Henry Schein by 17.2% in the fourth quarter. Olstein Capital Management L.P. now owns 109,000 shares of the company's stock worth $7,543,000 after buying an additional 16,000 shares during the last quarter. Private Management Group Inc. increased its stake in shares of Henry Schein by 5.7% in the 4th quarter. Private Management Group Inc. now owns 350,515 shares of the company's stock worth $24,256,000 after purchasing an additional 18,882 shares in the last quarter. Equitable Trust Co. bought a new position in Henry Schein in the 4th quarter worth $417,000. Savant Capital LLC lifted its position in Henry Schein by 43.9% during the fourth quarter. Savant Capital LLC now owns 4,651 shares of the company's stock valued at $322,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Henry Schein by 29.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,854 shares of the company's stock valued at $1,113,000 after purchasing an additional 3,650 shares during the period. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Price Performance

NASDAQ:HSIC traded down $1.06 during trading hours on Friday, reaching $65.17. The stock had a trading volume of 736,944 shares, compared to its average volume of 1,615,735. The company has a 50 day moving average price of $69.46 and a two-hundred day moving average price of $71.81. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a market capitalization of $7.98 billion, a PE ratio of 26.82, a PEG ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). The business had revenue of $3.19 billion during the quarter, compared to analysts' expectations of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.66 earnings per share. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HSIC has been the topic of several recent research reports. StockNews.com downgraded Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Bank of America raised shares of Henry Schein from an "underperform" rating to a "buy" rating and lifted their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. UBS Group reduced their price objective on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research note on Wednesday, February 26th. Barrington Research restated an "outperform" rating and set a $90.00 target price on shares of Henry Schein in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group boosted their price objective on Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a research report on Thursday, January 23rd. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Henry Schein currently has an average rating of "Moderate Buy" and an average target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.